Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report

The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yangyang, Wang, Yizhuo, Sun, Jingnan, Wang, Xu, Xu, Yinghui, Sun, Chao, Guo, Ye, Sun, Mengyao, Ma, Kewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273558/
https://www.ncbi.nlm.nih.gov/pubmed/32493093
http://dx.doi.org/10.1177/0300060520928793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273558/
https://www.ncbi.nlm.nih.gov/pubmed/32493093
http://dx.doi.org/10.1177/0300060520928793

Ejemplares similares